Workflow
康惠制药:子公司陕西友帮持续亏损、调整产品生产均不顺利,决定停产

Core Viewpoint - Kanghui Pharmaceutical announced the suspension of production at its subsidiary Shaanxi Youbang Biopharmaceutical Technology Co., Ltd. to reduce losses and protect shareholder interests [1][2] Group 1: Production Suspension - Shaanxi Youbang has suspended production in workshops 1, 2, and 3 due to ongoing losses and challenges in product adjustments and production processes [1] - The decision to suspend production aligns with the company's strategic direction to lower operational costs and mitigate further financial losses [1] Group 2: Financial Impact - In 2024, Shaanxi Youbang's total assets accounted for 16.91% of the company's latest audited total assets, while its revenue represented 1.42% of the consolidated revenue [2] - The net profit for Shaanxi Youbang in 2024 is projected to be -52.51 million, impacting the company's net profit attributable to shareholders by -26.78 million, which is 29.88% of the total [2] Group 3: Future Plans - The company will decide on the resumption of production based on market conditions and is actively seeking collaboration opportunities to maximize the asset value of Shaanxi Youbang [2]